Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs)...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-04-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137920300766 |
| _version_ | 1819014195222413312 |
|---|---|
| author | Fernanda Salles Seguro Carolina Maria Pinto Domingues Carvalho Silva Carla Maria Boquimpani de Moura Monika Conchon Laura Fogliatto Vaneuza Araujo Moreira Funke André Abdo Ariane Vieira Scarlatelli Macedo Marilia Harumi Higushi dos Santos José Francisco Kerr Saraiva |
| author_facet | Fernanda Salles Seguro Carolina Maria Pinto Domingues Carvalho Silva Carla Maria Boquimpani de Moura Monika Conchon Laura Fogliatto Vaneuza Araujo Moreira Funke André Abdo Ariane Vieira Scarlatelli Macedo Marilia Harumi Higushi dos Santos José Francisco Kerr Saraiva |
| author_sort | Fernanda Salles Seguro |
| collection | DOAJ |
| description | This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and from the perspective of hematology consultation.In the first medical appointment, the CV risk factors should be identified to perform the baseline risk stratification, based on the Brazilian Guideline of Dyslipidemia and Atherosclerosis Prevention Update (risk levels: very high, high, intermediate and low).Once stratified, the treatment of the CV risk factors should be administered. If the patient presents risk factors, such as hypertension, diabetes, renal disease, smoking and hypercholesterolemia, the evaluation and initial treatment may be done by the hematologist, being an option the request for evaluation by a specialist. If the patient has a history of previous CV disease, we recommend referral to a specialist.As the CV risk score is dynamic and the control of risk factors can reduce the patient risk, this expert consensus recommends that the re-evaluation of the CV risk after the baseline should be performed at 3 months, 6 months and 12 months. After this period, it should be done annually and, for specific patients, at the clinician’s discretion.The evaluation of the baseline CV risk and the safe administration of a TKI allow the patient to benefit from the maximum treatment, avoiding unwanted effects. |
| first_indexed | 2024-12-21T02:11:59Z |
| format | Article |
| id | doaj.art-6172ec3bee5447e2843ae019ef078a76 |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-12-21T02:11:59Z |
| publishDate | 2021-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-6172ec3bee5447e2843ae019ef078a762022-12-21T19:19:20ZengElsevierHematology, Transfusion and Cell Therapy2531-13792021-04-01432191200Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoringFernanda Salles Seguro0Carolina Maria Pinto Domingues Carvalho Silva1Carla Maria Boquimpani de Moura2Monika Conchon3Laura Fogliatto4Vaneuza Araujo Moreira Funke5André Abdo6Ariane Vieira Scarlatelli Macedo7Marilia Harumi Higushi dos Santos8José Francisco Kerr Saraiva9Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil; Instituto do Câncer do Estado de São Paulo, (ICESPSP), São Paulo, SP, Brazil; Corresponding author at: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Av. Dr. Enéas Carvalho de Aguiar, 255, Cerqueira César, São Paulo - SP, CEP: 05403-000, Brazil.Instituto do Câncer do Estado de São Paulo, (ICESPSP), São Paulo, SP, Brazil; Universidade de São Paulo (USP), São Paulo, SP, BrazilHEMORIO, Rio de Janeiro, RJ, BrazilHospital Santa Marcelina, São Paulo, SP, BrazilUniversidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil; Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, BrazilUniversidade Federal do Paraná (UFPR), Curtitiba, PR, BrazilInstituto do Câncer do Estado de São Paulo, (ICESPSP), São Paulo, SP, BrazilCentro Paulista de Oncologia, Grupo Oncoclínicas do Brasil, São Paulo, SP, BrazilInstituto do Câncer do Estado de São Paulo, (ICESPSP), São Paulo, SP, Brazil; Universidade de São Paulo (USP), São Paulo, SP, BrazilPontifícia Universidade Católica de Campinas, Faculdade de Medicina, SP, BrazilThis manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and from the perspective of hematology consultation.In the first medical appointment, the CV risk factors should be identified to perform the baseline risk stratification, based on the Brazilian Guideline of Dyslipidemia and Atherosclerosis Prevention Update (risk levels: very high, high, intermediate and low).Once stratified, the treatment of the CV risk factors should be administered. If the patient presents risk factors, such as hypertension, diabetes, renal disease, smoking and hypercholesterolemia, the evaluation and initial treatment may be done by the hematologist, being an option the request for evaluation by a specialist. If the patient has a history of previous CV disease, we recommend referral to a specialist.As the CV risk score is dynamic and the control of risk factors can reduce the patient risk, this expert consensus recommends that the re-evaluation of the CV risk after the baseline should be performed at 3 months, 6 months and 12 months. After this period, it should be done annually and, for specific patients, at the clinician’s discretion.The evaluation of the baseline CV risk and the safe administration of a TKI allow the patient to benefit from the maximum treatment, avoiding unwanted effects.http://www.sciencedirect.com/science/article/pii/S2531137920300766Cardiovascular diseasesLeukemia, myeloidProtein kinase inhibitorsRisk factorsRisk management |
| spellingShingle | Fernanda Salles Seguro Carolina Maria Pinto Domingues Carvalho Silva Carla Maria Boquimpani de Moura Monika Conchon Laura Fogliatto Vaneuza Araujo Moreira Funke André Abdo Ariane Vieira Scarlatelli Macedo Marilia Harumi Higushi dos Santos José Francisco Kerr Saraiva Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring Hematology, Transfusion and Cell Therapy Cardiovascular diseases Leukemia, myeloid Protein kinase inhibitors Risk factors Risk management |
| title | Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring |
| title_full | Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring |
| title_fullStr | Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring |
| title_full_unstemmed | Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring |
| title_short | Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring |
| title_sort | recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors risk assessment stratification treatment and monitoring |
| topic | Cardiovascular diseases Leukemia, myeloid Protein kinase inhibitors Risk factors Risk management |
| url | http://www.sciencedirect.com/science/article/pii/S2531137920300766 |
| work_keys_str_mv | AT fernandasallesseguro recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring AT carolinamariapintodominguescarvalhosilva recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring AT carlamariaboquimpanidemoura recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring AT monikaconchon recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring AT laurafogliatto recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring AT vaneuzaaraujomoreirafunke recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring AT andreabdo recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring AT arianevieirascarlatellimacedo recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring AT mariliaharumihigushidossantos recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring AT josefranciscokerrsaraiva recommendationsforthemanagementofcardiovascularriskinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitorsriskassessmentstratificationtreatmentandmonitoring |